Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
28 Febbraio 2023 - 10:01PM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), a clinical-stage oncology-focused cell therapy company,
today announced that it will report financial results for the
fourth quarter and full year ended December 31, 2022, on Tuesday,
March 7, 2023, before the open of U.S. markets. Following the
announcement, the Company will host a conference call and webcast
at 8:30 a.m. ET to review the financial results and provide a
corporate update.
Register for the live webcast using the link
here or by visiting the “Investors” section of the Alaunos website
at www.alaunos.com. To participate via telephone, please register
in advance at this link. Upon registration, all telephone
participants will receive a confirmation email detailing how to
join the conference call, including the dial-in number along with a
unique passcode and registrant ID that can be used to access the
call. The event will be archived on the Company’s website for
approximately 30 days after the call.
About Alaunos Therapeutics,
Inc.Alaunos Therapeutics is a leader in the science of
T-cell receptor (TCR) cell therapy working to revolutionize solid
cancer treatment and outcomes. The clinical-stage company’s TCR
T-cell therapy (TCR-T) is one of the most advanced TCR programs
targeting driver mutations in solid tumors with an ongoing Phase
1/2 trial of its TCR-T product candidates across six solid cancers.
Alaunos is powered by two proprietary platforms: its elegantly
efficient non-viral Sleeping Beauty cell engineering platform; and
its hunTR® discovery platform, which is expanding its
industry-leading library of TCRs against high-frequency driver
mutations. Alaunos is a part of an ongoing collaboration with the
National Cancer Institute (NCI), part of the National Institutes of
Health (NIH), working to advance the science of TCR therapy. For
more information, visit www.alaunos.com.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
Media Contact:Heather Anderson6
Degrees PRhanderson@6degreespr.com
Grafico Azioni Alaunos Therapeutics (NASDAQ:TCRT)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Alaunos Therapeutics (NASDAQ:TCRT)
Storico
Da Mag 2023 a Mag 2024